Assessment and Treatment of Psoriatic Arthritis

Introduction to Psoriatic Arthritis Treatment

The American College of Rheumatology (ACR) and National Psoriasis Foundation (NPF) guidelines recommend switching to a TNF inhibitor, like Simponi, after failing an IL-17 inhibitor, such as Cosentyx, for the treatment of psoriatic arthritis 1, 2
The Aetna CPB criteria require evidence of positive clinical response, as demonstrated by improvement in at least one parameter, including swollen joints, tender joints, dactylitis, enthesitis, axial disease, skin/nail involvement, functional status, or CRP, to approve continuation of therapy 2

The ACR/NPF guidelines suggest that adequate assessment of treatment response typically requires more than one month of therapy 1, 3
A therapeutic trial is considered adequate after treatment for more than 3 months, with more than 2 months at the standard target dose, according to the 2009 PsA treatment recommendations 4
Baseline and follow-up measures of disease activity should include the number of swollen/tender joints, presence of dactylitis or enthesitis, skin and nail involvement, functional status measures, and laboratory markers like CRP 2

The patient should continue current Simponi therapy for a full 3-month trial period to properly assess efficacy, as one month is insufficient to determine treatment failure with biologics 4, 5
If no improvement is observed after 3 months of Simponi therapy, consider switching to another TNF inhibitor or an IL-12/23 inhibitor, especially if the patient has severe psoriasis or contraindications to TNF inhibitors 1, 3, 6

Premature discontinuation of biologic therapy should be avoided, as most clinical trials evaluate response at 12-14 weeks minimum 4
Lack of objective measures, such as joint counts, skin scores, and inflammatory markers, can lead to improper assessment of response 2
Ignoring partial responses, where patients show improvement in certain domains but not others, can result in inadequate treatment 1

The American College of Rheumatology (ACR) and National Psoriasis Foundation (NPF) guidelines support provider judgment in adjusting biologic dosing based on individual patient response, particularly when patients demonstrate breakthrough symptoms on standard dosing intervals 7, 8
The ACR/NPF guidelines recognize that clinical practice often requires individualized dosing adjustments, and the FDA-approved dosing for Simponi Aria may need to be adjusted based on patient response 7

The ACR/NPF guidelines recommend switching to a TNF inhibitor after IL-17 failure, which supports the patient's treatment history of failing Cosentyx (IL-17 inhibitor) and switching to golimumab (TNF inhibitor) 7
The guidelines also support switching to a different TNF inhibitor after failing one TNF inhibitor, which is consistent with the patient's history of failing Humira (TNF inhibitor) and switching to golimumab 7, 8
The patient's failure of conventional DMARD (leflunomide) due to GI intolerance and avoidance of methotrexate due to presumed NASH are valid reasons for continuing golimumab therapy 7, 8

The ACR/NPF guidelines emphasize the importance of documenting hepatitis B status before initiating TNF inhibitor therapy, which is a requirement for continued golimumab therapy 7

The ACR/NPF guidelines recommend achieving low disease activity as the treatment target, and the patient's clinical documentation indicates achievement of this goal with sustained clinical stability on 6-week dosing 7